The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial

Haematologica

Volumn 98, Issue 6, 2013, Pages 945-952

  Marks, David I ^a   Moorman, Anthony V ^b   Chilton, Lucy ^b   Paietta, Elisabeth ^c   Enshaie, Amir ^b   de Wald, Gordon ^d   Harrison, Christine J ^b   Fielding, Adele K ^e   Foroni, Letizia ^f   Goldstone, Anthony H ^e   Litzow, Mark R ^d   Luger, Selina M ^g   McMillan, Andrew K ^h   Racevskis, Janis ^c   Rowe, Jacob M ⁱ   Tallman, Martin S ^j   Wiernik, Peter ^c   Lazarus, Hillard M ^k  

^a UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h NOTTINGHAM CITY HOSPITAL   (United Kingdom)

ⁱ SHAARE ZEDEK MEDICAL CENTER   (Israel)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CD11B ANTIGEN; CD123 ANTIGEN; CD133 ANTIGEN; CD135 ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD24 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; ENDOGLIN; HLA DR ANTIGEN; METHOTREXATE; MICROSOMAL AMINOPEPTIDASE; STEM CELL FACTOR RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CYTOGENETICS; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; CAUSE OF DEATH; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 4; FEMALE; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; TRANSLOCATION, GENETIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878427232     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.081877     Document Type: Article

References (34)

1. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/ maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111 (4):1827-33.
2. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, et al. Induction therapy for adults with acute lymphoblastic leukaemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG 2993. Blood. 2005;106(12):3760-7.
3. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, et al. Karyotype is an independent prognostic factor in acute lymphoblastic leukaemia: analysis of cytogenetic data from patients treated on the MRC UKALL XII/ECOG 2993 trial. Blood. 2007;109(8): 3189-97.
4. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009;114(25): 5136-45.
5. Moorman AV. The clinical relevance of chromosomal and genomic abnormalities in B cell precursor acute lymphoblastic leukaemia. Blood Rev. 2012;26(3):123-35.
6. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007; 370(9583):240-50.
7. Greaves M. Pre-natal origins of childhood leukemia. Rev Clin Exp Hematol. 2003;7 (3):233-45.
8. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758-64.
9. Bardini M, Galbiati M, Lettieri A, Bungaro S, Gorletta TA, Biondi A, et al. Implementation of array based wholegenome high-resolution technologies confirms the absence of secondary copy-number alterations in MLL-AF4-positive infant ALL patients. Leukemia. 2011;25(1):175-8.
10. Marschalek R. Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol. 2011;152(2):141-54.
11. Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol. 2010;11(5): 429-38.
12. Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE, et al. Key pathways are frequently mutated in high risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011;118(11): 3080-7.
13. Mahgoub N, Parker RI, Hosler MR, Close P, Winick NJ, Masterson M, et al. RAS mutations in pediatric leukemias with MLL gene rearrangements. Genes Chromosomes Cancer. 1998;21(3):270-5.
14. Stam RW, den Boer ML, Schneider P, Meier M, Beverloo HB, Pieters R. D-HPLC analysis of the entire FLT-3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. Haematologica. 2007;92(11): 1565-8.
15. Stumpel DJ, Schneider P, van Roon EH, Boer JM, de Lorenzo P, Valsecchi MG, et al. Specific promoter methylation identifies different subgroups of MLL rearranged infant acute lymphoblastic leukemia, influences clinical outcome and provides therapeutic options. Blood. 2009;114(27):5490-8.
16. Geng H, Brennan S, Milne TA, Chen WY, Li Y, Hurtz C, et al. Integrative epigenomic analysis of adult B-acute lymphoblastic leukemia identifies biomarkers and therapeutic targets. Cancer Discov. 2012;2(11): 1004-23.
17. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardised RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia. 1999;13 (12):1901-28.
18. Mantel N, Byar DP. Evaluation of responsetime data involving transient states: an illustration using heart-transplant data. J Am Stat Assoc. 1974;69:81-6.
19. Paietta E. Immunobiology of acute leukemia. In: Wiernik P, Dutcher J, Goldman J, Kyle R, eds. Neoplastic Diseases of the Blood, 4th Edition. Cambridge, UK: Cambridge University Press; 2003:194-231.
20. Marks DI, Wang T, Pérez WS, Antin JH, Copelan E, Gale RP, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010;116(3):366-74.
21. Mohty M, Labopin M, Volin L, Gratwohl A, Socié G, Esteve J. Acute Leukemia Working Party of EBMT. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116(22): 4439-43.
22. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukaemia (ALL); an MRC UKALL XII/ECOG 2993 study. Blood. 2007;109(3):944-50.
23. Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011(18);29:2493-8.
24. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4): 403-11.
25. Sverdlow SH, Camp E, Harris NL et al. Eds. WHO classification of tumour of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, Lyon, 2008.
26. Rai L, Casanova A, Moorman AV, Richards S, Buck G, Goldstone AH, et al. Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cellorigin of ALL subgroups-a UKALLXII study. Br J Haematol. 2010;148(3):394-401.
27. Litzow MR, Buck GAN, Paietta E et al. Outcome of 1229 adult Philadelphia chromosome negative B-lineage acute lymphoblastic leukemia patients on the international UK ALL XII-ECOG2993 trial. (manuscript in preparation)
28. Schwab CJ, Jones LR, Morrison H, Ryan SL, Yigittop H, Schouten JP, et al. Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2010;49(12):1104-13.
29. De Zen L, Bicciato S, te Kronnie G, Basso G. Computational analysis of flow-cytometry antigen expression profiles in childhood acute lymphoblastic leukemia: an MLL/AF4 identification. Leukemia. 2003;17(8):1557-65.
30. Cox CV, Diamanti P, Evely RS, Kearns PR, Blair A. Expression of CD133 on leukemia initiating cells in childhood ALL. Blood. 2009;113(14):3287-96.
31. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30(1):41-7.
32. Moorman AV, Schwab C, Ensor HM, Russell LJ, Morrison H, Jones L, et al. IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J Clin Oncol. 2012; 30(25):3100-8.
33. Bernt KM, Armstrong SA. Targeting epigenetic programs in MLL-rearranged leukemias. Hematology Am Soc Hematol Educ Program. 2011;2011:354-60.
34. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011;20(1):53-65.